---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-242960"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2024-10-24T23:59:59+00:00"
generated_at: "2026-05-30T10:29:11.267999+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Guardant appoints Roberto Mignone (Bridger Management) to board of directors

## Summary
- Guardant expands board to 10; appoints Roberto Mignone as Class I director effective Oct 21, 2024.
- Founder and Managing Partner of Bridger Management, a healthcare-focused investment firm.
- Appointed to audit committee; receives initial equity awards totaling $725,000 vesting over 4 years.
- Appointment follows FDA approval of Shield blood test for early-stage colorectal cancer screening.
- Also serves on Teva Pharmaceuticals board and as co-Vice Chairman of NYU Langone Medical Center.

## SEC filing metadata
- accession: 0001193125-24-242960
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2024-10-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000119312524242960/0001193125-24-242960-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000119312524242960/d763358d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-242960
- JSON: https://secwatch.observer/filing/0001193125-24-242960.json
- Plain text: https://secwatch.observer/filing/0001193125-24-242960.txt

## Key facts
- Executive change
  Roberto Mignone was appointed as Class I Director at Guardant Health, Inc..
  - Action: appointed
  - Role: Class I Director
  source text: On October 21, 2024, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to ten and appointed Roberto Mignone., as a Class I director of the Company, to be effective as of October 21, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000119312524242960/0001193125-24-242960-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.